Improving supportive care of young patients with breast cancer
According to Prof. Ann Partridge, 2024 ESMO Awardee, young patients with breast cancer have unique needs that must be addressed to achieve better outcomes
Do young patients benefit from immune checkpoint inhibitors?
First evidence for the efficacy of anti-PD-1 agents in children, adolescents and young adults with melanoma prompts the call for a change in cancer care for this population
Pregnancy after breast cancer: study provides reassurance to BRCA carriers undergoing assisted reproductive techniques
No difference in risk recurrence or pregnancy outcomes was reported between young women with BRCA1 or BRCA2 mutations conceiving naturally and those using fertility treatments
Health emergencies: let’s get prepared without leaving cancer patients behind
ESMO is advocating for secondary and tertiary care levels to be included into international agreements and WHO’s documents to respond to pandemics
Pregnancy after cancer- is it safe?
While increasing evidence from studies support pregnancy after cancer treatment, data gaps persist, particularly regarding the impact of novel therapies on fertility
Access to high-quality care for sarcomas is still unequal worldwide
Delays and poor patient journey are reported in resource-constrained countries, while awareness campaigns and healthcare service reorganisation have improved rare cancer management in more developed areas
COVID-19 vaccination is key to restoring early-phase anticancer drug development
Vaccination among cancer patients should not affect their participation in clinical trials and levels of acceptance of the vaccine are high
Optimising clinical trials for greater inclusiveness
Oncologists are aiming to capitalise on lessons learned from the COVID-19 pandemic and design more inclusive clinical trials, optimise trial endpoints and make better use of real-world evidence.
Innovation is creating new ways to support oncologists
How ESMO is transforming the challenges from the COVID-19 pandemic into opportunities to re-shape the future of the oncology community
Should we invest more in registry data?
During the COVID-19 pandemic, real-world data have shown they can support clinical decision-making in complex situations but extensive bureaucracy is still a limiting factor